These conjugates were tested in vivo by either direct vaccination or ex vivo DC loading prior to vaccination. Both approaches show similar effectiveness in CTL priming.

We have shown recently that the T cell stimulatory capacity of DCs pulsed with tumorantigen-derived peptides can be considerably increased by activating the DCs through electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA (TriMix DCs). This vaccine will also be tested in the multicentre trial.

We established tumor cell lines from renal cell cancer in our laboratory.

We established tumor cell lines from pancreatic cancer in our laboratory.

In order to identify the APCs that were responsible for the development of this state of immune tolerance, we aimed to generate a transgenic mouse that express a recombinant fluorescent protein in the mammary glands, an approach that should result in high levels of expression of the fluorescent protein in the milk. We thus should be able to detect the cells that capture, degrade and present this antigen to T cells. Since we had previously generated a monoclonal antibody, 2C44, that reacts to a peptide derived from the Leishmania LACK protein bound to I-Ad MHC ...

These monocyte-derived dendritic cells are loaded with tumor lysate generated from the excised metastatic lesion of stage III/IV melanoma patients. They will be used for vaccine generation.

This tumor lysate is from patients with advanced (stage III or IV) melanoma. It is used for the generation of a vaccine and loading of DC.

Used for stimulation in the evaluation of the role of Src kinases in DCs during synergic engagement of TLR8 with either TLR4 or TLR3.

Used for stimulation in the evaluation of the role of Src kinases in DCs during synergic engagement of TLR8 with either TLR4 or TLR3.

Used for stimulation in the evaluation of the role of Src kinases in DCs during synergic engagement of TLR8 with either TLR4 or TLR3.

We have efficiently transfected DC with RNA encoding a functional protein (E/L-selectin), which allows entry of DC into LN from HEV. These DC rolled in vitro on sialyl-LewisX-coated slides, and in vivo, mouse E/L-selectin-transfected DC homed to LN after i.v. application.

This tumor RNA was used to transfect matured DC with the final aim to produce a DC vaccine.

TNF alpha was used for DC maturation with the final aim to produce a DC vaccine.

The DC are transfected with RNA encoding MelanA, Mage3 and Survivin +/- E/L-selectin. They are used in the DERMA-ER-DC 06 trial.

TNF-alpha is used during maturation of the DCs.

This tissue was taken from a surgical resection of a melanotic lesion. The electrophoresis product will then be used to generate dendritic cells from the monocytes which in their turn will be used as vaccines.

The immature monocyte-derived dendritic cells where transduced with high doses of lentiviral vectors to monitor activation of the immature DC.

Immature DC (imDC´s) are transfected with different constructs encoding for the oncogene Her-2/neu and as control PSA. The technology of Amaxa biosystems or an adeno virus Her-2 full length construct are used.

The peptides are used in the generation of monocyte-derived DC (pulsing of the cells at a concentration of 5 µg/mL in approximately 5 mL and at a cell density of 20 x 10e6/mL for 1 h.).

Commercially available siRNA Smart Pool from Dharmacon targeted against the STAT3 transcription factor have been successfully transfected in human MDDCs.